## CRM: Salesforce, Inc. - XLK: Technology

### Executive Summary

VALUE thesis: PEG 1.13 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($246.30)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Salesforce, Inc. Just Recorded A 35% EPS Beat: Here's What Analysts Are Forecasting Next**
- Source: Simply Wall Street | 20251207T140742 | Somewhat-Bullish | Relevance: 99%
- Salesforce, Inc. surprised analysts by delivering a 35% EPS beat, with profits reaching US$2.19 per share, although revenues of US$10 billion were in line with expectations. Following these results, analysts project revenues of US$45.9 billion for 2027, an increase from previous forecasts, while the consensus price target remains steady at US$327. Despite the revenue upgrade, Salesforce is expected to grow slower than its industry peers.

**2. Salesforce Inc. $CRM Stock Holdings Lowered by Vega Investment Solutions**
- Source: MarketBeat | 20251208T130819 | Somewhat-Bullish | Relevance: 99%
- Vega Investment Solutions significantly reduced its stake in Salesforce by 35.3% in Q2, selling 9,996 shares and retaining 18,297 shares valued at $4.99 million. Insider activity was mixed, with a director buying shares and the CEO selling some, while analysts maintain a "Moderate Buy" rating with an average target price of $326.54 for CRM. The company reported strong Q results, beating EPS expectations.

**3. Dir Morfit Buys 96,000 ($25M) Of Salesforce Inc [CRM]**
- Source: TradingView | 20251208T141427 | Neutral | Relevance: 99%
- Salesforce Inc. Director, G. Mason Morfit, purchased 96,000 shares of CRM stock on December 5, 2025, at a price of $260.58 per share, totaling over $25 million. This transaction increased Morfit's indirect holdings to 2,994,509 shares. The information was disclosed in a Form 4 filed with the SEC.

**4. Salesforce (CRM) Reports Q3 2026 Results, Wall Street Bullish**
- Source: Yahoo Finance Singapore | 20251209T164157 | Bullish | Relevance: 99%
-  Salesforce (NYSE: CRM) reported its fiscal Q3 2026 results, showing an 8.63% year-over-year revenue increase to $10.26 billion and an EPS of $3.25, surpassing consensus estimates. The company raised its full-year guidance based on a strong performance, particularly in Agentforce and Data 360 ARR, and current remaining performance obligation growth. Wall Street analysts reiterated "Buy" ratings, with one firm raising its price target to $395.

**5. Salesforce (CRM) Reports Q3 2026 Results, Wall Street Bullish**
- Source: Insider Monkey | 20251209T170756 | Bullish | Relevance: 99%
-  Salesforce (CRM) reported its fiscal Q3 2026 results, showing an 8.63% year-over-year revenue growth to $10.26 billion, despite slightly missing revenue expectations. The company's EPS of $3.25, however, exceeded consensus, leading to a more than 5% stock surge and a bullish outlook from Wall Street analysts. Management also raised its full-year guidance, driven by strong performance in Agentforce and Data 360 ARR.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 6, Lowers: 10)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Morgan Stanley | $398 | $405 | -2% |
| 2025-12-08 | Citigroup | $257 | $253 | +2% |
| 2025-12-05 | DA Davidson | $235 | $225 | +4% |
| 2025-12-04 | Truist Securiti | $380 | $400 | -5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Morgan Stanley | main | Overweight |
| 2025-12-08 | Citigroup | main | Neutral |
| 2025-12-05 | DA Davidson | main | Neutral |
| 2025-12-04 | Truist Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 29 ($26.85M) |
| Sells | 31 ($1.90M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.8%)
- Blackrock Inc.: 8.5% (-0.5%)
- State Street Corpora: 5.2% (+0.3%)
- JPMORGAN CHASE & CO: 2.7% (+46.5%)
- Geode Capital Manage: 2.2% (+0.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 6 raises (avg +4%) could attract flows.
- Momentum building: MRS_20 improving +7.7% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.13 suggests fair value with growth premium. Quality metrics strong (margin 18%). Balance sheet: $2.2B free cash flow. Analyst sentiment negative (10 target cuts vs 6 raises). Insider buying signal ($26.9M), management confidence. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $248.5B |
| Beta | 1.25 |
| 52W Range | $221.96 - $367.09 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.13 |
| Forward P/E | 20.0 |
| Current P/E | 22.2 |
| YoY Growth | 10.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.8% to 6.9% (+7.7% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 88th percentile. MRS_5 at 2.8% confirms short-term momentum alignment. AM_20 at 9.2% shows strong absolute momentum above own 20MA. Outperforming sector by 5.6pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (3.94), confirming momentum. Elevated volume (1.4x 20MA), institutional activity likely.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.92% (CS: 89) | Strong |
| RSI_14 | 66.1 | Neutral |
| MACD Histogram | 3.94 | Bullish |
| vs SMA20 | 1.092x | Above |
| vs SMA50 | 1.069x | Above |
| vs SMA200 | 1.008x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $261.02
- **Stop Loss:** $246.30 (5.6% risk)
- **Target:** $290.46 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 81
- **Position Value:** $21,142.62
- **Portfolio %:** 21.14%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-25 (Est: $3.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $2.86 | $3.25 | +13.6% |
| 2025Q3 | $2.78 | $2.91 | +4.7% |
| 2025Q2 | $2.55 | $2.58 | +1.3% |
| 2025Q1 | $2.61 | $2.78 | +6.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*